vs
Side-by-side financial comparison of Globavend Holdings Ltd (GVH) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $13.7M, roughly 1.4× Globavend Holdings Ltd). Globavend Holdings Ltd runs the higher net margin — 3.3% vs -90.7%, a 94.0% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 63.7%). Globavend Holdings Ltd produced more free cash flow last quarter ($-1.2M vs $-37.8M).
Globavend Holdings Ltd is a provider of smart unattended retail solutions, focusing on the design, supply, and operation of intelligent vending machines. It primarily serves markets across Australia, New Zealand, and Southeast Asia, offering end-to-end services including hardware manufacturing, inventory management software, and after-sales support to clients in retail, FMCG, and workplace service segments.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
GVH vs NAMS — Head-to-Head
Income Statement — Q1 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.7M | $19.1M |
| Net Profit | $450.3K | $-17.4M |
| Gross Margin | 10.5% | — |
| Operating Margin | 5.8% | -186.1% |
| Net Margin | 3.3% | -90.7% |
| Revenue YoY | 63.7% | 740.1% |
| Net Profit YoY | -49.9% | 55.5% |
| EPS (diluted) | $6.01 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $19.1M | ||
| Q1 25 | $13.7M | — | ||
| Q4 24 | — | $12.8M | ||
| Q3 24 | — | $29.1M | ||
| Q1 24 | $8.4M | — | ||
| Q2 23 | — | $8.6M |
| Q2 25 | — | $-17.4M | ||
| Q1 25 | $450.3K | — | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | — | $-16.6M | ||
| Q1 24 | $898.8K | — | ||
| Q2 23 | — | $-42.0M |
| Q2 25 | — | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | 19.8% | — | ||
| Q2 23 | — | — |
| Q2 25 | — | -186.1% | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | — | -85.9% | ||
| Q1 24 | 13.8% | — | ||
| Q2 23 | — | -461.8% |
| Q2 25 | — | -90.7% | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | — | -57.2% | ||
| Q1 24 | 10.7% | — | ||
| Q2 23 | — | -486.9% |
| Q2 25 | — | $-0.15 | ||
| Q1 25 | $6.01 | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q1 24 | $12.57 | — | ||
| Q2 23 | — | $-0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $915.2K | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.7M | $778.5M |
| Total Assets | $6.4M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $739.2M | ||
| Q1 25 | $915.2K | — | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q1 24 | $2.5M | — | ||
| Q2 23 | — | — |
| Q2 25 | — | $778.5M | ||
| Q1 25 | $5.7M | — | ||
| Q4 24 | — | $757.5M | ||
| Q3 24 | — | $378.9M | ||
| Q1 24 | $4.4M | — | ||
| Q2 23 | — | $398.4M |
| Q2 25 | — | $815.1M | ||
| Q1 25 | $6.4M | — | ||
| Q4 24 | — | $864.6M | ||
| Q3 24 | — | $439.2M | ||
| Q1 24 | $6.0M | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-906.3K | $-37.7M |
| Free Cash FlowOCF − Capex | $-1.2M | $-37.8M |
| FCF MarginFCF / Revenue | -8.8% | -197.2% |
| Capex IntensityCapex / Revenue | 2.2% | 0.5% |
| Cash ConversionOCF / Net Profit | -2.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-37.7M | ||
| Q1 25 | $-906.3K | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.5M | ||
| Q1 24 | $-256.6K | — | ||
| Q2 23 | — | $-31.9M |
| Q2 25 | — | $-37.8M | ||
| Q1 25 | $-1.2M | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q1 24 | $-730.0K | — | ||
| Q2 23 | — | $-31.9M |
| Q2 25 | — | -197.2% | ||
| Q1 25 | -8.8% | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q1 24 | -8.7% | — | ||
| Q2 23 | — | -369.3% |
| Q2 25 | — | 0.5% | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q1 24 | 5.6% | — | ||
| Q2 23 | — | 0.1% |
| Q2 25 | — | — | ||
| Q1 25 | -2.01× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | -0.29× | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
